Novogen of Australia Reports Favorable Trial For Pancreatic Cancer Drug
This article was originally published in PharmAsia News
Australia's Novogen said it received favorable reports from trials on its triphendiol for treating pancreatic cancer. The drug was tried in combination with Eli Lilly's Gemzar (gemcitabine hydrochloride). The Sydney-based company recently announced positive results for its promensil product for maintaining ovarian cancer remission in addition to its use for treating menopausal symptoms. (Click here for more
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.